BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
Bionor Pharma - Expiry of subscription period and last day of trading in subscription rights tomorrow
(Oslo, Norway, 28 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the "Prospectus") dated 14 September 2016 concerning the rights issue (the "Rights Issue") of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR").
Subscription rights for participation in the Rights Issue can be exercised during the ongoing subscription period, which will expire tomorrow, 29 September 2016, at 16:30 CET.
The period for trading in subscription rights (ticker "BIONOR-T") for the Rights Issue will also expire tomorrow, 29 September 2016 at 16:30 CET.
Subscription rights that are not used to subscribe for new shares or not sold before the expiry of the subscription period will have no value and will lapse without compensation to the holder.
For more information, please refer to the Prospectus. The Prospectus is, subject to regulatory restrictions in certain jurisdictions, available on the following website: www.sb1markets.no . Hard copies of the Prospectus may be obtained by contacting the Company (telephone: +47 23 01 09 60) or SpareBank 1 Markets (telephone: +47 24 14 74 00).
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bionor Pharma's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com .
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan, Hong Kong or the United States (including its territories and possessions, any state of the United States and the District of Columbia).
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia Canada, Japan, Hong Kong or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor SpareBank 1 Markets AS assumes any responsibility in the event there is a violation by any person of such restrictions.
The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.Bionor_SEA20160928_LastDayOfTradingSubscriptionRightsTomorrow
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.